{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T13:21:09Z","timestamp":1770816069943,"version":"3.50.1"},"reference-count":17,"publisher":"American Society for Microbiology","issue":"4","license":[{"start":{"date-parts":[[2003,4,1]],"date-time":"2003-04-01T00:00:00Z","timestamp":1049155200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["J Clin Microbiol"],"published-print":{"date-parts":[[2003,4]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:p>The TRUGENE<jats:italic>HIV-1<\/jats:italic>Genotyping Kit and OpenGene DNA Sequencing System are designed to sequence the protease (PR)- and reverse transcriptase (RT)-coding regions of human immunodeficiency virus type 1 (HIV-1)<jats:italic>pol<\/jats:italic>. Studies were undertaken to determine the accuracy of this assay system in detecting resistance-associated mutations and to determine the effects of RNA extraction methods, anticoagulants, specimen handling, and potentially interfering substances. Samples were plasma obtained from HIV-infected subjects or seronegative plasma to which viruses derived from wild-type and mutant infectious molecular clones (IMC) of HIV-1 were added. Extraction methods tested included standard and UltraSensitive AMPLICOR HIV-1 MONITOR, QIAGEN viral RNA extraction mini kit, and QIAGEN Ultra HIV extraction kit, and NASBA manual HIV-1 quantitative NucliSens. Sequence data from test sites were compared to a \u201cgold standard\u201d reference sequence to determine the percent agreement. Comparisons between test and reference sequences at the nucleotide level showed 97.5 to 100% agreement. Similar results were obtained regardless of extraction method, regardless of use of EDTA or acid citrate dextrose as anticoagulant, and despite the presence of triglycerides, bilirubin, hemoglobin, antiretroviral drugs, HIV-2, hepatitis C virus (HCV), HBV, cytomegalovirus, human T-cell leukemia virus type 1 (HTLV-1), or HTLV-2. Samples with HIV-1 RNA titers of \u22651,000 copies\/ml gave consistent results. The TRUGENE<jats:italic>HIV-1<\/jats:italic>Genotyping Kit and OpenGene DNA Sequencing System consistently generate highly accurate sequence data when tested with IMC-derived HIV and patient samples.<\/jats:p>","DOI":"10.1128\/jcm.41.4.1594-1599.2003","type":"journal-article","created":{"date-parts":[[2003,4,7]],"date-time":"2003-04-07T20:34:54Z","timestamp":1049747694000},"page":"1594-1599","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":54,"title":["Performance Characteristics of the TRUGENE<i>HIV-1<\/i>Genotyping Kit and the Opengene DNA Sequencing System"],"prefix":"10.1128","volume":"41","author":[{"given":"Daniel R.","family":"Kuritzkes","sequence":"first","affiliation":[{"name":"Division of Infectious Diseases, University of Colorado Health Sciences Center, Denver, Colorado"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert M.","family":"Grant","sequence":"additional","affiliation":[{"name":"Gladstone Institute of Virology and Immunology, San Francisco"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Feorino","sequence":"additional","affiliation":[{"name":"Visible Genetics, Inc., Suwanee, Georgia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marshal","family":"Griswold","sequence":"additional","affiliation":[{"name":"Consolidated Laboratories, Van Nuys, California"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie","family":"Hoover","sequence":"additional","affiliation":[{"name":"Advanced BioMedical Laboratories, Cinnaminson, New Jersey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Russell","family":"Young","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, University of Colorado Health Sciences Center, Denver, Colorado"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen","family":"Day","sequence":"additional","affiliation":[{"name":"Visible Genetics, Inc., Suwanee, Georgia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"Jr.","given":"Robert M.","family":"Lloyd,","sequence":"additional","affiliation":[{"name":"Visible Genetics, Inc., Suwanee, Georgia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caroline","family":"Reid","sequence":"additional","affiliation":[{"name":"Visible Genetics, Inc., Toronto, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gillian F.","family":"Morgan","sequence":"additional","affiliation":[{"name":"Visible Genetics, Inc., Toronto, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dean L.","family":"Winslow","sequence":"additional","affiliation":[{"name":"Visible Genetics, Inc., Toronto, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"crossref","unstructured":"Baxter J. D. D. L. Mayers D. N. Wentworth J. D. Neaton M. L. Hoover M. A. Winters S. B. Mannheimer M. A. Thompson D. I. Abrams B. J. Brizz J. P. A. Ioannidis T. C. Merigan and the CPCRA 046 Study Team for the Terry Berin Community Programs for Clinical Research on AIDS (CPCRA). 2000. A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy. AIDS 14: F83-F93.","DOI":"10.1097\/00002030-200006160-00001"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200201040-00001"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-122-6-199503150-00001"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1086\/314775"},{"key":"e_1_3_2_6_2","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1177\/135965350000500112","volume":"5","year":"2000","unstructured":"DeGruttola, V., L. Dix, R. D'Aquila, D. Holder, A. N. Phillips, M. Ait-Khaled, J. D. Baxter, P. Clevenbergh, S. Hammer, R. P. Harrigan, D. Katzenstein, R. Lanier, M. D. Miller, M. Para, S. Yerly, A. R. Zolopa, J. S. Murray, A. Patick, V. Miller, S. Castillo, L. Pedneault, and J. Mellors. 2000. The relation between baseline HIV drug resistance and response to antiretroviral therapy: re-analysis of retrospective and prospective studies using a standardized data analysis plan. Antivir. Ther.5:41-48.","journal-title":"Antivir. Ther."},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.36.4.1070-1073.1998"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(98)12291-2"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200102160-00003"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.41.4.1586-1593.2003"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.283.18.2417"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1128\/jcm.29.4.676-679.1991"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1128\/jcm.33.6.1562-1566.1995"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/171.5.1172"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/167.3.526"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.282.12.1142"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200201250-00010"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-131-11-199912070-00003"}],"container-title":["Journal of Clinical Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/JCM.41.4.1594-1599.2003","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/JCM.41.4.1594-1599.2003","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,26]],"date-time":"2023-04-26T05:05:29Z","timestamp":1682485529000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/JCM.41.4.1594-1599.2003"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,4]]},"references-count":17,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2003,4]]}},"alternative-id":["10.1128\/JCM.41.4.1594-1599.2003"],"URL":"https:\/\/doi.org\/10.1128\/jcm.41.4.1594-1599.2003","relation":{},"ISSN":["0095-1137","1098-660X"],"issn-type":[{"value":"0095-1137","type":"print"},{"value":"1098-660X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,4]]},"assertion":[{"value":"2002-02-11","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2003-01-09","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2003-04-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}